# Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

> **NCT01680588** · PHASE2 · UNKNOWN · sponsor: **Navidea Biopharmaceuticals** · enrollment: 70 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [18F]NAV4694

## Key facts

- **NCT ID:** NCT01680588
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680588, "Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01680588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*